Multicenter, open-label, safety and tolerability study of ascending doses of HepaStem in patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH) to determine the safety and tolerability of ascending single and repeated doses of HepaStem administered to patients with cirrhotic and pre-cirrhotic non-alcoholic steato-hepatitis (NASH)
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
23
Heterologous human adult liver-derived progenitor cells
CUB Erasme
Brussels, Belgium
Cliniques Universitaires St Luc
Brussels, Belgium
University Hospital Antwerp (UZA)
Edegem, Belgium
Incidence of Adverse Event
Safety and Tolerability
Time frame: up to Day 28
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
UZ Gent
Ghent, Belgium
University Multiprofile Hospital for Active Treatment "Tsaritsa Yoana - ISUL"
Sofia, Bulgaria
Multiprofile hospital for active treatment (MHAT) Sofia Military Medical Academy
Sofia, Bulgaria
Trakia Park Hospital
Stara Zagora, Bulgaria
CHU Bordeaux
Bordeaux, France
Paul Brousse Hospital
Villejuif, France
Vall d'Hebron
Barcelona, Spain
...and 3 more locations